MoneyWorks4Me

Concord Biotech - Quaterly Results

11 Nov 2024 Evaluate
The Revenue for the quarter ended  September 2024 of Rs. 3101.81 millions grew by 18.23 % from Rs. 2623.46 millions.A humble growth in net profit of 16.81% reported in the quarter ended September 2024 to Rs. 987.00  millions from Rs. 844.94 millions.Operating profit surged to 1467.04 millions from the corresponding previous quarter of 1273.15 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 3101.81 2623.46 18.23 5259.83 4571.74 15.05 10169.39 8531.68 19.20
Other Income 100.26 81.26 23.38 203.34 147.80 37.58 337.80 353.09 -4.33
PBIDT 1467.04 1273.15 15.23 2382.90 2061.22 15.61 4653.37 3785.96 22.91
Interest 0.96 8.41 -88.59 3.37 15.94 -78.86 25.52 45.10 -43.41
PBDT 1466.08 1264.74 15.92 2379.53 2045.28 16.34 4627.85 3740.86 23.71
Depreciation 133.14 132.95 0.14 264.92 263.36 0.59 535.92 540.32 -0.81
PBT 1332.94 1131.79 17.77 2114.61 1781.92 18.67 4091.93 3200.54 27.85
TAX 345.94 286.85 20.60 545.22 452.27 20.55 1044.62 819.28 27.50
Deferred Tax 5.35 9.29 -42.41 10.69 11.71 -8.71 46.28 23.82 94.29
PAT 987.00 844.94 16.81 1569.39 1329.65 18.03 3047.31 2381.26 27.97
Equity 104.62 104.62 0.00 104.62 104.62 0.00 104.62 104.62 0.00
PBIDTM(%) 47.30 48.53 -2.54 45.30 45.09 0.48 45.76 44.38 3.12
Peers
Company Name CMP
Sun Pharma. Inds. 1842.00
Dr. Reddys Labs. 1161.00
Cipla 1365.00
Lupin 2096.00
Zydus Lifesciences 1119.50
View more..